B-SOFT's share price drop may be linked to its shift into a loss-making position. Last year's performance suggests unresolved challenges, worse than the annualised loss of 8% over the last half decade. Investors should ensure they're buying a high-quality business, even in a falling market.
B-SOFTLtd's falling ROCE and sales, coupled with rising capital employment, suggest a potential loss in competitive edge or market share. A positive shift in these metrics is needed for it to remain a viable investment.
Investors' skepticism about B-SOFTLtd's strong revenue growth prospects may be causing its low P/S ratio. Despite forecasted growth, the market questions these estimates, anticipating future revenue volatility.
The continuous decline in B-SOFTLtd's ROCE despite increasing capital coupled with falling revenue is worrying. Persisting trends may indicate a firm losing market share while trying to reinvest for growth. Exploring other investment opportunities could be wise if these trends endure.
创业慧康股票讨论区
DBS: China Healthcare Sector – Pharmaceutical Packaging
$微创医疗(00853.HK)$$威高股份(01066.HK)$$石药集团(01093.HK)$$国药控股(01099.HK)$$华润医疗(01515.HK)$$康臣药业(01681.HK)$$春立医疗(01858.HK)$$环球医疗(02666.HK)$$复宏汉霖(02696.HK)$$创业慧康(300451.SZ)$$柳药集团(603368.SH)$$百济神州(06160.HK)$
DBS: China Biotech Sector
$百济神州(06160.HK)$$石药集团(01093.HK)$$复宏汉霖(02696.HK)$$微创医疗(00853.HK)$$威高股份(01066.HK)$$国药控股(01099.HK)$$华润医疗(01515.HK)$$康臣药业(01681.HK)$$春立医疗(01858.HK)$$环球医疗(02666.HK)$$复宏汉霖(02696.HK)$$创业慧康(300451.SZ)$$柳药集团(603368.SH)$$百济神州(06160.HK)$
暂无评论